Latest news with #cancercare
Yahoo
15 hours ago
- Business
- Yahoo
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
We recently compiled a list of ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body's natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy. In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients. Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia's health system will bring the Cancer BioShield platform to the Middle East. The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles. A laboratory technician using high tech equipment to sequence cancer genomics. By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours after the call concludes. ABOUT LEGEND BIOTECH With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities. Learn more at and follow us on X (formerly Twitter) and LinkedIn. INVESTOR CONTACT:Jessie YeungTel: (732) PRESS CONTACT:Mary Ann OndishTel: (914) 552-4625media@ in to access your portfolio
Yahoo
17-07-2025
- Health
- Yahoo
AI-Supported, Single-Center Cancer Model from Liv Hospital
Photo: Liv Hospital via FL Communications ISTANBUL, July 17, 2025 (GLOBE NEWSWIRE) -- The 'single-center oncology model,' implemented by only a select number of institutions worldwide, is being carried out with advanced technology and artificial intelligence at Liv Hospital. The model brings together all stages of cancer care—diagnosis, treatment, follow-up, and even home-based care—under one roof, with personalized treatment plans guided by multidisciplinary tumor boards and AI-driven clinical decision systems. Every patient at Liv Hospital begins a tailored care journey based on their unique genetic profile, health status, and lifestyle factors. Traditional one-size-fits-all protocols have been replaced by individualized, algorithmically guided therapies. Asst. Prof. Meltem Topalgökçeli Selam, MD, Medical Oncologist at Liv Hospital: 'We no longer offer identical chemotherapy protocols to every patient. Instead, each person receives a treatment uniquely aligned with their biology. AI analyzes genetic markers, lifestyle, age, and immune function within seconds to recommend the most effective drug combination based on scientific data. This makes the process faster, more accurate, and far more predictable.' Photo: Liv Hospital Multidisciplinary Collaboration: From a Single Decision-Making Center Liv Hospital's Oncology Council includes specialists in medical oncology, radiation oncology, nuclear medicine, hematology, general surgery, pathology, and genetics. These experts work together to design individualized treatment roadmaps, ensuring full coordination from initial diagnosis to long-term care. Photo: Liv Hospital State-of-the-art technology plays a critical role in enabling this model. Liv Hospital is equipped with the latest generation imaging systems, radiotherapy devices, robotic surgical platforms, and high-capacity support infrastructure, including heavy-duty cranes that facilitate the installation and safe maintenance of high-precision medical equipment. For pediatric cases, a separate clinical infrastructure is in place. Pediatric hematologists, oncologists, surgeons, ICU physicians, psychologists, and nutrition specialists operate as part of a dedicated Pediatric Oncology Board. Treatment is administered in specialized pediatric intensive care units, with a focus on hygiene, isolation protocols, and age-specific psychosocial support. Each child receives comprehensive care designed with sensitivity to both medical and emotional needs. Academic Foundation, Clinical Precision: The Liv Model More than just a healthcare institution, Liv Hospital is also a research-driven center operating in partnership with Istinye University. A majority of Liv physicians also serve as academic faculty, enabling rapid translation of cutting-edge medical research into clinical practice. AI-supported systems continuously analyze patient data—including clinical, genetic, and biological inputs—to determine which treatment combinations produce the highest success rates. This ensures that care is not only personalized but also scientifically validated through real-time analytics. Through Liv Academy, the hospital offers on-site education and training for international healthcare professionals, providing firsthand exposure to the Liv Hospital oncology model. This positions Liv Hospital not only as a center of care, but as a global reference point in medical education and knowledge sharing. A New Chapter in Cancer Treatment: CAR-T Cell Therapy at Liv Hospital Liv Hospital is preparing to introduce CAR-T cell therapy, one of the most groundbreaking cancer treatments available today. Considered among the most advanced options for certain hematologic cancers, CAR-T involves modifying a patient's own immune cells to fight cancer more effectively. Photo: Liv Hospital Liv Hospital has signed a strategic collaboration agreement with the University of Pennsylvania (UPenn), the institution where CAR-T therapy was originally developed. This partnership allows Liv to implement the latest protocols and best practices in CAR-T treatment within its own facilities. Media Contact: FL PR and Communications +905330202554 asset@ Photos accompanying this announcement are available at: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or pre-funded warrant ('Pre-Funded Warrant') in lieu thereof) and one warrant (the 'Warrants'). Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and offering expenses. Each Warrant is immediately exercisable, and entitles the holder to purchase one common share at an exercise price of $1.50 per share and will expire five years from the date of issuance. The common shares (or Pre-Funded Warrants) and Warrants can only be purchased together in the offering but will be issued separately. The offering is expected to close on July 16, 2025, subject to satisfaction of customary closing conditions. No Canadian prospectus has been or will be filed in a province or territory of Canada to qualify the securities in connection with the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq. The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives. ThinkEquity is acting as the sole placement agent for the offering. A registration statement on Form S-1 (File No. 333-288562) relating to the securities was filed with the Securities and Exchange Commission ('SEC') and became effective on July 15, 2025. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About BriaCell Therapeutics BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at Forward Looking StatementsThis press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' "will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the final prospectus related to the public offering that will be filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@ Investor Relations Contact:investors@ 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
CBC
14-07-2025
- Health
- CBC
Prince County Hospital's intensive-care unit to reopen in August, administrator confirms
Prince County Hospital in Summerside is preparing to restore two crucial health services next month, including the reopening of its intensive-care unit and resuming in-person oncologist appointments. The eight-bed ICU has been closed since May 2023 due to a lack of specialized staff. Since then, more serious intensive-care cases have been handled at the Queen Elizabeth Hospital in Charlottetown, 60 kilometres away. "It's been a couple of years before we've been able to offer this specific level of critical-care services, and we're very much looking forward to the opportunity to do that again," Rob Philpott, Prince County Hospital's administrator, told CBC's Island Morning on Monday. Cancer care Cancer patients in western P.E.I. will once again be able to see an oncologist in person at PCH as of Aug. 11. Earlier this month, CBC News reported that cancer patients in the region had to travel to Charlottetown for chemotherapy treatments until July 10 due to staffing shortages in the oncology department at Prince County Hospital, while those who need to see a medical oncologist would have to travel to Charlottetown until the end of August or earlier. Philpott said that for the next four weeks the hospital will be able to treat patients who have low-risk treatments — in other words, a low risk of any reactions to medication — with remote oncology support. "Then as of the week of Aug. 11, we expect to be, I'll say back to normal in terms of our clinic appointments available here at PCH, because from that point forward we'll have clinic appointments [that] will be face-to-face with an oncologist." Prince County Hospital has two full-time oncologists who also provide part-time coverage at the Queen Elizabeth Hospital. Philpott said only one is working this summer due to the other being on vacation and education leave. He said the plan for a third medical oncologist to join the team at the QEH's Cancer Treatment Centre is still on schedule for mid-September. Continued travel for some cancer treatments While services are returning to Prince County Hospital, Philpott noted there will still be instances where patients will need to travel to the Cancer Treatment Centre in Charlottetown. This includes patients who need radiation therapy, which is only offered at the QEH, as well as those with new cancer diagnoses who require their first consultation there. "This would also extend to patients who may not necessarily be new to the cancer service, but are also seen for the very first time by a new oncologist, so that will never change," Philpott said.
